Glenmark rises armed with research after five year hiatus Industry-The Economic Times — October 14, 2016 comments off It may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.
It may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.